135 related articles for article (PubMed ID: 20414937)
1. Matrix metalloproteinases and proangiogenic factors in testicular germ cell tumors.
Diamantopoulos N; Boutis AL; Koratzis I; Andreadis C; Galaktidou G; Mouratidou D; Kortsaris A
J BUON; 2010; 15(1):116-21. PubMed ID: 20414937
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
3. Systemic regulation of angiogenesis and matrix degradation in bone regeneration--distraction osteogenesis compared to rigid fracture healing.
Weiss S; Zimmermann G; Baumgart R; Kasten P; Bidlingmaier M; Henle P
Bone; 2005 Dec; 37(6):781-90. PubMed ID: 16202678
[TBL] [Abstract][Full Text] [Related]
4. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
5. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors.
Bentas W; Beecken WD; Glienke W; Binder J; Schuldes H
Urol Res; 2003 Feb; 30(6):390-3. PubMed ID: 12599020
[TBL] [Abstract][Full Text] [Related]
7. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease.
Kang HS; Kim JH; Phi JH; Kim YY; Kim JE; Wang KC; Cho BK; Kim SK
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844
[TBL] [Abstract][Full Text] [Related]
8. Imbalance of MMP-2 and MMP-9 expression versus TIMP-1 and TIMP-2 reflects increased invasiveness of human testicular germ cell tumours.
Milia-Argeiti E; Huet E; Labropoulou VT; Mourah S; Fenichel P; Karamanos NK; Menashi S; Theocharis AD
Int J Androl; 2012 Dec; 35(6):835-844. PubMed ID: 22712465
[TBL] [Abstract][Full Text] [Related]
9. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
Oszajca K; Szemraj M; Szemraj J; Jurowski P
Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
11. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
13. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
14. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Rudek MA; Figg WD; Dyer V; Dahut W; Turner ML; Steinberg SM; Liewehr DJ; Kohler DR; Pluda JM; Reed E
J Clin Oncol; 2001 Jan; 19(2):584-92. PubMed ID: 11208854
[TBL] [Abstract][Full Text] [Related]
18. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic factors in plasma of brain tumour patients.
Ilhan A; Gartner W; Neziri D; Czech T; Base W; Hörl WH; Wagner L
Anticancer Res; 2009 Feb; 29(2):731-6. PubMed ID: 19331229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
